2022 was an important year for triglyceride-related research, with extensive clinical and preclinical data presented at international congresses and published in leading journals. When we asked Editorial Advisory Board members for their highlights, they agreed that the PROMINENT trial of triglyceride (TG) lowering to reduce cardiovascular (CV) risk, published in November 2022, was a major milestone.1 Although TG lowering with the PPARa agonist, pemafibrate, did not reduce CV events in patients with type 2 diabetes, mild-to-moderate hypertriglyceridaemia and low HDL- and LDL-cholesterol levels, PROMINENT results have stimulated valuable discussion about the role of apolipoprotein B-containing lipoproteins in CV risk.